With the rise of unilateral protectionism and the blockage of World Trade Organization(WTO)multilateral trading system reform,the United States(U.S.)provides huge financial support to its semiconductor industry throug...With the rise of unilateral protectionism and the blockage of World Trade Organization(WTO)multilateral trading system reform,the United States(U.S.)provides huge financial support to its semiconductor industry through the“Chip Act.”Besides,the U.S.attempts to improve the competitiveness of its semiconductor industry and dominate the international semiconductor market by setting up a series of“guardrails provisions”to curb the development of“foreign countries of concern,”such as China.Through documentary analysis,the main contents of the“Chip Act”are clarified,and its justiciability and compliance are analyzed from the perspective of WTO rules.In terms of actionability,the“Chip Act”meets the general conditions of subsidies and possesses the traits of specificity but at the same time causes damage to other countries’industries,thus constituting an actionable subsidy.In terms of compliance,the discriminatory provisions of the“Chip Act”violate the principle of non-discrimination.Accordingly,China should actively respond under the WTO framework by promoting the resolution of the Appellate Body crisis and the reform of the dispute settlement mechanism as well as participating in subsidy reform negotiations and contributing Chinese solutions;China should also take the initiative to apply countervailing rules to the“Chip Act”while improving its own trade remedy system.展开更多
AIM To assess the efficacy and safety of combined directly acting antivirals(DAAs) for the treatment of Chinese chronic hepatitis C(CHC) patients in a real-world setting.METHODS Hospitalized CHC patients who were trea...AIM To assess the efficacy and safety of combined directly acting antivirals(DAAs) for the treatment of Chinese chronic hepatitis C(CHC) patients in a real-world setting.METHODS Hospitalized CHC patients who were treated with DAAs at Peking University First Hospital between January 2015 and December 2016 were enrolled. Samples and clinical data were collected at 0 wk, 2 wk, 4 wk, 8 wk, 12 wk, or 24 wk during DAAs treatment and at 4 wk, 12 wk, and 24 wk after the end of treatment. RESULTS Fifty-four patients who underwent DAAs treatment were included in our study, of whom 83.3%(45/54) achieved rapid virological response at 2 wk after treatment initiation(RVR 2) and 94.4%(51/54)achieved sustained virological response at 24 wk after the end of treatment(SVR 24). Serum creatinine and uric acid levels at the end of treatment were significantly increased compared with baseline levels(83.6 ± 17.9 vs 88.8 ± 19.4, P 01 < 0.001; 320.8 ± 76.3 vs 354.5 ± 87.6, P 01 < 0.001), and no significant improvements were observed at 24 w after the end of treatment(83.6 ± 17.9 vs 86.8 ± 19.1, P 02 = 0.039; 320.8 ± 76.3 vs 345.9 ± 89.4, P 02 = 0.001). The total frequency of adverse events(AEs) during treatment was 33.3%(18/54), with major AEs being fatigue(16.7%), headache(7.4%), anorexia(7.4%), and insomnia(5.6%). CONCLUSION Though based in a small cohort of patients, the abnormal changes in renal function indices and relative high frequency of AEs during combined DAAs treatment should be taken as a note of caution.展开更多
Major advances have been made in the treatment of chronic hepatitis C virus(HCV) infection with the advent of direct-acting antiviral agents(DAAs). China has the most cases of HCV infection worldwide, but none of the ...Major advances have been made in the treatment of chronic hepatitis C virus(HCV) infection with the advent of direct-acting antiviral agents(DAAs). China has the most cases of HCV infection worldwide, but none of the DAAs has been approved in China's Mainland so far, and interferon(IFN)-α-based treatment remains the standard of care. HCV patients without response or with contraindications to IFN-based therapy have no alternative options. However, many patients buy DAAs, especially the generic forms of sofosbuvir, from other countries or areas. Under these circumstances, the use of these drugs may cause many predictable and unpredictable problems in ethics, law and medical practice. Given the obstacles of legal accessibility to DAAs and the potential problems of obtaining and using DAAs in China, the early launching of the DAAs in China or the legalization of buying drugs from areas outside China and using these drugs in China is an urgent issue and needs to be dealt with as soon as possible, in the interest of the patients.展开更多
Because that American government and congress hold a negative attitude on responding to climate change issue, people transfer the battle stage of climate change to the court,and hope to promote government and large en...Because that American government and congress hold a negative attitude on responding to climate change issue, people transfer the battle stage of climate change to the court,and hope to promote government and large energy companies actively responding to climate change issue via litigation form. A large amount of related litigation appears,and a kind of special litigation type is gradually formed, namely climate change litigation. National Environmental Policy Act of the United States is one of important legal weapons used by prosecutor in climate change litigation. In National Environmental Policy Act, it stipulates environmental impact evaluation system which has close relationship with climate change litigation. The system requires that federal agency ＂ should compile detailed environmental impact report （EIS） on major federal action which significantly affects human survival environment quality＂. Litigation case of Export - Import Bank of the United States and Overseas Private Investment Corporation by Fdends of the Earth, Green Peace, Boulder City, etc. is typical one related to the act. We try to evaluate and analyze text and case of the act.展开更多
文摘With the rise of unilateral protectionism and the blockage of World Trade Organization(WTO)multilateral trading system reform,the United States(U.S.)provides huge financial support to its semiconductor industry through the“Chip Act.”Besides,the U.S.attempts to improve the competitiveness of its semiconductor industry and dominate the international semiconductor market by setting up a series of“guardrails provisions”to curb the development of“foreign countries of concern,”such as China.Through documentary analysis,the main contents of the“Chip Act”are clarified,and its justiciability and compliance are analyzed from the perspective of WTO rules.In terms of actionability,the“Chip Act”meets the general conditions of subsidies and possesses the traits of specificity but at the same time causes damage to other countries’industries,thus constituting an actionable subsidy.In terms of compliance,the discriminatory provisions of the“Chip Act”violate the principle of non-discrimination.Accordingly,China should actively respond under the WTO framework by promoting the resolution of the Appellate Body crisis and the reform of the dispute settlement mechanism as well as participating in subsidy reform negotiations and contributing Chinese solutions;China should also take the initiative to apply countervailing rules to the“Chip Act”while improving its own trade remedy system.
基金Supported by National Natural Science Foundation of China,No.81373056Beijing Municipal Committee of Science and Technology,No.D161100002716003National Major Project for Infectious Diseases Control,No.2012ZX10002003-004-003
文摘AIM To assess the efficacy and safety of combined directly acting antivirals(DAAs) for the treatment of Chinese chronic hepatitis C(CHC) patients in a real-world setting.METHODS Hospitalized CHC patients who were treated with DAAs at Peking University First Hospital between January 2015 and December 2016 were enrolled. Samples and clinical data were collected at 0 wk, 2 wk, 4 wk, 8 wk, 12 wk, or 24 wk during DAAs treatment and at 4 wk, 12 wk, and 24 wk after the end of treatment. RESULTS Fifty-four patients who underwent DAAs treatment were included in our study, of whom 83.3%(45/54) achieved rapid virological response at 2 wk after treatment initiation(RVR 2) and 94.4%(51/54)achieved sustained virological response at 24 wk after the end of treatment(SVR 24). Serum creatinine and uric acid levels at the end of treatment were significantly increased compared with baseline levels(83.6 ± 17.9 vs 88.8 ± 19.4, P 01 < 0.001; 320.8 ± 76.3 vs 354.5 ± 87.6, P 01 < 0.001), and no significant improvements were observed at 24 w after the end of treatment(83.6 ± 17.9 vs 86.8 ± 19.1, P 02 = 0.039; 320.8 ± 76.3 vs 345.9 ± 89.4, P 02 = 0.001). The total frequency of adverse events(AEs) during treatment was 33.3%(18/54), with major AEs being fatigue(16.7%), headache(7.4%), anorexia(7.4%), and insomnia(5.6%). CONCLUSION Though based in a small cohort of patients, the abnormal changes in renal function indices and relative high frequency of AEs during combined DAAs treatment should be taken as a note of caution.
文摘Major advances have been made in the treatment of chronic hepatitis C virus(HCV) infection with the advent of direct-acting antiviral agents(DAAs). China has the most cases of HCV infection worldwide, but none of the DAAs has been approved in China's Mainland so far, and interferon(IFN)-α-based treatment remains the standard of care. HCV patients without response or with contraindications to IFN-based therapy have no alternative options. However, many patients buy DAAs, especially the generic forms of sofosbuvir, from other countries or areas. Under these circumstances, the use of these drugs may cause many predictable and unpredictable problems in ethics, law and medical practice. Given the obstacles of legal accessibility to DAAs and the potential problems of obtaining and using DAAs in China, the early launching of the DAAs in China or the legalization of buying drugs from areas outside China and using these drugs in China is an urgent issue and needs to be dealt with as soon as possible, in the interest of the patients.
文摘Because that American government and congress hold a negative attitude on responding to climate change issue, people transfer the battle stage of climate change to the court,and hope to promote government and large energy companies actively responding to climate change issue via litigation form. A large amount of related litigation appears,and a kind of special litigation type is gradually formed, namely climate change litigation. National Environmental Policy Act of the United States is one of important legal weapons used by prosecutor in climate change litigation. In National Environmental Policy Act, it stipulates environmental impact evaluation system which has close relationship with climate change litigation. The system requires that federal agency ＂ should compile detailed environmental impact report （EIS） on major federal action which significantly affects human survival environment quality＂. Litigation case of Export - Import Bank of the United States and Overseas Private Investment Corporation by Fdends of the Earth, Green Peace, Boulder City, etc. is typical one related to the act. We try to evaluate and analyze text and case of the act.
